397 related articles for article (PubMed ID: 29601324)
1. Neisseria gonorrhoeae vaccine development: hope on the horizon?
Edwards JL; Jennings MP; Seib KL
Curr Opin Infect Dis; 2018 Jun; 31(3):246-250. PubMed ID: 29601324
[TBL] [Abstract][Full Text] [Related]
2. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
[TBL] [Abstract][Full Text] [Related]
3. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
Reyes Díaz LM; Lastre González MSJB; Cuello M; Sierra-González VG; Ramos Pupo R; Lantero MI; Harandi AM; Black S; Pérez O
Pediatr Infect Dis J; 2021 Apr; 40(4):375-381. PubMed ID: 33591079
[TBL] [Abstract][Full Text] [Related]
4. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.
Semchenko EA; Tan A; Borrow R; Seib KL
Clin Infect Dis; 2019 Sep; 69(7):1101-1111. PubMed ID: 30551148
[TBL] [Abstract][Full Text] [Related]
5. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
[TBL] [Abstract][Full Text] [Related]
6. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
[TBL] [Abstract][Full Text] [Related]
7. Exploitation of
Petousis-Harris H; Radcliff FJ
Front Immunol; 2019; 10():683. PubMed ID: 31024540
[TBL] [Abstract][Full Text] [Related]
8. Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development.
Rice PA; Shafer WM; Ram S; Jerse AE
Annu Rev Microbiol; 2017 Sep; 71():665-686. PubMed ID: 28886683
[TBL] [Abstract][Full Text] [Related]
9. The potential impact of vaccination on the prevalence of gonorrhea.
Craig AP; Gray RT; Edwards JL; Apicella MA; Jennings MP; Wilson DP; Seib KL
Vaccine; 2015 Aug; 33(36):4520-4525. PubMed ID: 26192351
[TBL] [Abstract][Full Text] [Related]
10. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.
Edwards JL; Jennings MP; Apicella MA; Seib KL
Crit Rev Microbiol; 2016 Nov; 42(6):928-41. PubMed ID: 26805040
[TBL] [Abstract][Full Text] [Related]
11. Promising developments in gonococcal vaccines.
Waltmann A; Chen JS; Duncan JA
Curr Opin Infect Dis; 2024 Feb; 37(1):63-69. PubMed ID: 38050729
[TBL] [Abstract][Full Text] [Related]
12. Evaluating vaccine-elicited antibody activities against
Gray MC; Thomas KS; Lamb ER; Werner LM; Connolly KL; Jerse AE; Criss AK
Infect Immun; 2023 Dec; 91(12):e0030923. PubMed ID: 37991382
[TBL] [Abstract][Full Text] [Related]
13. Progress Toward a Gonococcal Vaccine: The Way Forward.
Russell MW; Jerse AE; Gray-Owen SD
Front Immunol; 2019; 10():2417. PubMed ID: 31681305
[TBL] [Abstract][Full Text] [Related]
14. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
Régnier SA; Huels J
Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
[TBL] [Abstract][Full Text] [Related]
15. Biological feasibility and importance of a gonorrhea vaccine for global public health.
Vincent LR; Jerse AE
Vaccine; 2019 Nov; 37(50):7419-7426. PubMed ID: 29680200
[TBL] [Abstract][Full Text] [Related]
16. Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against
Seib KL; Donovan B; Thng C; Lewis DA; McNulty A; Fairley CK; Yeung B; Jin F; Fraser D; Bavinton BR; Law M; Chen MY; Chow EPF; Whiley DM; Mackie B; Jennings MP; Jennison AV; Lahra MM; Grulich AE
BMJ Open; 2024 Apr; 14(4):e081675. PubMed ID: 38626958
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates.
Baarda BI; Zielke RA; Holm AK; Sikora AE
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536323
[TBL] [Abstract][Full Text] [Related]
18. Neisseria proteomics for antigen discovery and vaccine development.
Christodoulides M
Expert Rev Proteomics; 2014 Oct; 11(5):573-91. PubMed ID: 25017717
[TBL] [Abstract][Full Text] [Related]
19. Structure of the Recombinant
Almonacid-Mendoza HL; Humbert MV; Dijokaite A; Cleary DW; Soo Y; Hung MC; Orr CM; Machelett MM; Tews I; Christodoulides M
mSphere; 2018 Oct; 3(5):. PubMed ID: 30305317
[No Abstract] [Full Text] [Related]
20. Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway.
Whelan J; Kløvstad H; Haugen IL; Holle MR; Storsaeter J
Emerg Infect Dis; 2016 Jun; 22(6):1137-9. PubMed ID: 27191543
[No Abstract] [Full Text] [Related]
[Next] [New Search]
